Resource Center

May 7, 2019
  |  Presentation

Assessing and Managing DILI Risk in Trials: A Consultant’s Perspective

Thoughts on the New Guidance

1). Define “signatures of DILI”

2). Encourage mechanistic research

3). Encourage novel use of DILI biomarkers and eDISH

US FDA & AASLD DILI Conference at the University of Maryland University College May 7-8, 2019

By Paul B Watkins

Contact Us About This Presentation